VNRX
VolitionRx Limited AMEX Listed Mar 2, 2012$1.40
+2.94%
vs $1.36
Mkt Cap $7.5M
52w Low $1.21
1.3% of range
52w High $15.50
50d MA $2.09
200d MA $5.34
P/E (TTM)
-0.3x
EV/EBITDA
—
P/B
—
Debt/Equity
-0.3x
ROE
68.2%
P/FCF
-0.4x
RSI (14)
46.40
ATR (14)
$0.12
Beta
1.33
50d MA
$2.09
200d MA
$5.34
Avg Volume
340.0K
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
13215 Bee Cave Parkway · Henderson, TX 78738 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.70 | -1.00 | -42.9% | 4.04 | -5.0% | -1.0% | -14.2% | -1.5% | -0.6% | +4.2% | — |
| Nov 13, 2025 | AMC | -0.04 | -0.04 | +0.0% | 7.09 | +3.4% | -6.6% | -4.5% | +10.8% | -6.4% | +1.8% | — |
| Aug 14, 2025 | AMC | -0.05 | -0.06 | -20.0% | 12.88 | +4.0% | +7.9% | -1.7% | -1.5% | -1.9% | +3.2% | — |
| May 15, 2025 | AMC | -0.06 | -0.06 | +0.0% | 9.07 | +1.4% | -5.2% | -2.6% | +17.2% | +4.2% | +1.1% | — |
| Mar 31, 2025 | AMC | -0.06 | -0.06 | +0.0% | 11.40 | -1.8% | -9.0% | +4.2% | +3.1% | -4.5% | -6.1% | — |
| Nov 14, 2024 | AMC | -0.07 | -0.07 | +0.0% | 14.40 | -2.8% | -5.6% | -2.4% | +1.0% | +20.9% | +0.1% | — |
| Aug 14, 2024 | AMC | -0.09 | -0.08 | +11.1% | 11.05 | -0.5% | +3.2% | +4.7% | +0.5% | +10.2% | +2.9% | — |
| May 13, 2024 | AMC | -0.11 | -0.10 | +9.1% | 17.55 | -0.9% | -14.5% | +4.9% | +1.7% | -3.8% | -3.0% | — |
| Mar 26, 2024 | AMC | -0.10 | -0.11 | -6.5% | 15.00 | -1.6% | -0.9% | +1.9% | +2.2% | +0.1% | -2.8% | — |
| Nov 15, 2023 | AMC | -0.12 | -0.11 | +8.3% | 15.26 | +2.2% | -0.4% | -1.6% | -2.3% | -7.6% | +8.1% | — |
| Aug 15, 2023 | AMC | -0.13 | -0.14 | -7.7% | 24.20 | +0.8% | -1.7% | +9.2% | +0.0% | -3.8% | +0.0% | — |
| May 11, 2023 | AMC | -0.14 | -0.15 | -7.1% | 37.80 | -1.1% | -6.3% | -2.8% | -5.8% | -3.1% | -1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | D. Boral Capital | Downgrade | Buy → Hold | — | $3.58 | $3.39 | -5.3% | -8.9% | -3.7% | +0.3% | -8.6% | -2.8% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.00 | $3.86 | -3.5% | -14.2% | -1.5% | -0.6% | +4.2% | -1.4% |
| Mar 31 | D. Boral Capital | Maintains | Buy → Buy | — | $3.80 | $3.80 | +0.0% | +6.3% | -1.0% | -14.2% | -1.5% | -0.6% |
| Mar 26 | D. Boral Capital | Maintains | Buy → Buy | — | $3.83 | $3.75 | -2.1% | +0.8% | +1.8% | -3.3% | +6.3% | -1.0% |
| Mar 18 | D. Boral Capital | Maintains | Buy → Buy | — | $3.80 | $5.78 | +52.1% | +5.3% | -5.0% | -1.6% | +9.9% | -2.2% |
| Jan 21 | D. Boral Capital | Maintains | Buy → Buy | — | $6.36 | $6.40 | +0.6% | -8.3% | -0.9% | -2.4% | -5.3% | -0.2% |
| Jan 9 | D. Boral Capital | Maintains | Buy → Buy | — | $7.10 | $6.76 | -4.8% | -6.2% | +2.1% | -7.4% | -4.4% | -3.2% |
| Dec 18 | D. Boral Capital | Maintains | Buy → Buy | — | $5.34 | $5.51 | +3.2% | +0.2% | -4.3% | +4.5% | -4.9% | -1.0% |
| Dec 4 | D. Boral Capital | Maintains | Buy → Buy | — | $5.69 | $5.79 | +1.8% | +9.5% | -3.9% | -0.7% | +1.7% | -7.4% |
| Dec 3 | Maxim Group | Downgrade | Buy → Hold | — | $5.97 | $5.80 | -2.8% | -4.7% | +9.5% | -3.9% | -0.7% | +1.7% |
| Nov 26 | D. Boral Capital | Maintains | Buy → Buy | — | $5.98 | $5.98 | +0.0% | +4.2% | +3.2% | -9.3% | +2.4% | -4.7% |
| Nov 21 | Freedom Broker | Maintains | Buy → Buy | — | $6.67 | $6.60 | -1.0% | -3.4% | +3.1% | -9.9% | +4.2% | +3.2% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.62 | $7.00 | +5.7% | -4.5% | +10.8% | -6.4% | +1.8% | -3.4% |
| Nov 17 | D. Boral Capital | Maintains | Buy → Buy | — | $6.62 | $7.00 | +5.7% | -4.5% | +10.8% | -6.4% | +1.8% | -3.4% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.46 | $13.00 | +4.3% | +9.0% | -8.4% | +0.6% | +3.6% | -0.5% |
| Sep 29 | D. Boral Capital | Maintains | Buy → Buy | — | $12.10 | $12.00 | -0.8% | +3.0% | +9.0% | -8.4% | +0.6% | +3.6% |
| Sep 10 | D. Boral Capital | Maintains | Buy → Buy | — | $12.74 | $12.90 | +1.3% | -2.5% | +1.0% | +4.5% | -4.0% | +1.6% |
| Aug 15 | D. Boral Capital | Maintains | Buy → Buy | — | $12.88 | $13.40 | +4.0% | +7.9% | -1.7% | -1.5% | -1.9% | +3.2% |
| Jul 17 | D. Boral Capital | Maintains | Buy → Buy | — | $14.00 | $14.18 | +1.3% | -3.4% | -0.2% | +14.8% | -4.6% | -0.5% |
| Jul 9 | D. Boral Capital | Maintains | Buy → Buy | — | $14.11 | $14.44 | +2.3% | -6.3% | +2.9% | -1.8% | +2.5% | -5.6% |
| Apr 30 | D. Boral Capital | Maintains | Buy → Buy | — | $10.12 | $10.34 | +2.2% | -5.1% | +1.6% | -2.6% | +5.3% | +4.0% |
| Apr 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.68 | $10.04 | +3.7% | +0.8% | +2.9% | -3.0% | +2.7% | -2.0% |
| Apr 1 | D. Boral Capital | Maintains | Buy → Buy | — | $11.40 | $11.20 | -1.8% | -9.0% | +4.2% | +3.1% | -4.5% | -6.1% |
| Mar 31 | D. Boral Capital | Maintains | Buy → Buy | — | $11.00 | $10.67 | -3.0% | +3.6% | -9.0% | +4.2% | +3.1% | -4.5% |
| Mar 20 | D. Boral Capital | Maintains | Buy → Buy | — | $11.14 | $10.80 | -3.1% | -2.2% | +1.0% | -0.4% | +0.9% | -6.9% |
| Mar 13 | D. Boral Capital | Maintains | Buy → Buy | — | $11.32 | $11.80 | +4.2% | +2.8% | -3.6% | +1.6% | -4.4% | +2.2% |
| Mar 12 | D. Boral Capital | Maintains | Buy → Buy | — | $11.80 | $11.40 | -3.4% | -4.1% | +2.8% | -3.6% | +1.6% | -4.4% |
| Mar 4 | D. Boral Capital | Maintains | Buy → Buy | — | $12.36 | $11.80 | -4.5% | +0.3% | -6.3% | +5.2% | -1.0% | -4.1% |
| Feb 6 | D. Boral Capital | Maintains | Buy → Buy | — | $11.68 | $12.16 | +4.1% | +6.1% | -3.1% | -3.0% | +0.7% | -0.9% |
| Jan 29 | D. Boral Capital | Maintains | Buy → Buy | — | $12.34 | $12.00 | -2.8% | -1.5% | +2.9% | -4.8% | +0.2% | -2.0% |
| Jan 8 | D. Boral Capital | Maintains | Buy → Buy | — | $13.20 | $13.20 | +0.0% | -4.5% | +3.5% | -4.8% | +6.3% | -4.5% |
| Dec 10 | D. Boral Capital | Maintains | Buy → Buy | — | $11.80 | $11.60 | -1.7% | -1.4% | +11.9% | -6.3% | -7.4% | +9.9% |
| Nov 15 | D. Boral Capital | Maintains | Buy → Buy | — | $14.40 | $14.00 | -2.8% | -5.6% | -2.4% | +1.0% | +20.9% | +0.1% |
| Nov 1 | EF Hutton | Maintains | Buy → Buy | — | $11.00 | $11.77 | +7.0% | +9.9% | -0.7% | +0.0% | +0.3% | +9.3% |
| Jun 7 | EF Hutton | Maintains | Buy → Buy | — | $13.80 | $13.88 | +0.6% | -1.4% | -1.5% | +10.4% | -6.4% | -2.5% |
| May 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.74 | $15.73 | -0.1% | +1.7% | -3.8% | -3.0% | -3.6% | +0.5% |
| May 14 | EF Hutton | Maintains | Buy → Buy | — | $17.55 | $17.40 | -0.9% | -14.5% | +4.9% | +1.7% | -3.8% | -3.0% |
| Mar 27 | EF Hutton | Maintains | Buy → Buy | — | $15.00 | $14.76 | -1.6% | -0.9% | +1.9% | +2.2% | +0.1% | -2.8% |
| Mar 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.00 | $14.76 | -1.6% | -0.9% | +1.9% | +2.2% | +0.1% | -2.8% |
| Jan 2 | EF Hutton | Maintains | Buy → Buy | — | $14.34 | $15.86 | +10.6% | +46.4% | +10.5% | -18.1% | +0.4% | -5.6% |
| Nov 21 | EF Hutton | Maintains | Buy → Buy | — | $14.61 | $14.60 | -0.1% | -7.6% | +8.1% | +1.9% | +3.4% | +1.0% |
| Nov 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.26 | $15.60 | +2.2% | -0.4% | -1.6% | -2.3% | -7.6% | +8.1% |
| Aug 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $24.20 | $24.40 | +0.8% | -1.7% | +9.2% | +0.0% | -3.8% | +0.0% |
| Feb 1 | Benchmark | Downgrade | Buy → Hold | — | $49.40 | $48.20 | -2.4% | -4.0% | -0.8% | -5.1% | -3.1% | -1.9% |
| Aug 23 | Maxim Group | Maintains | Buy → Buy | — | $32.00 | $31.60 | -1.2% | -0.6% | +5.7% | +3.0% | -2.3% | -4.7% |
| Aug 15 | Aegis Capital | Maintains | Buy → Buy | — | $41.00 | $41.00 | +0.0% | -2.0% | -2.0% | -5.1% | +2.1% | -1.6% |
| Nov 16 | Aegis Capital | Maintains | Buy → Buy | — | $82.60 | $82.60 | +0.0% | -3.6% | -5.8% | +4.5% | -0.8% | -5.4% |
| Jan 25 | Aegis Capital | Maintains | Buy → Buy | — | $89.20 | $98.00 | +9.9% | +12.1% | +1.8% | -9.8% | +2.6% | -2.1% |
| Aug 19 | Aegis Capital | Maintains | Buy → Buy | — | $69.80 | $70.00 | +0.3% | -0.3% | +1.7% | -2.3% | +2.0% | -0.6% |
No insider trades available.
8-K · 8.01
!! High
VolitionRx Limited -- 8-K 8.01: Material Event / Announcement
Jun 10
8-K · 1.01
!! High
VolitionRx Limited -- 8-K 1.01: Material Agreement
May 22
8-K · 2.02
!! High
VolitionRx Limited -- 8-K 2.02: Earnings Results
May 14
8-K · 8.01
!! High
VolitionRX Limited -- 8-K 8.01: Material Event / Announcement
VolitionRX Limited announced material developments via press release on April 23, 2026, following NYSE American disclosure procedures, though specific details warrant review of the full press release for investment impact assessment.
Apr 23
8-K · 8.01
!! High
VolitionRX Limited -- 8-K 8.01: Material Event / Announcement
VolitionRX's reverse stock split will round up fractional shares to whole shares, benefiting shareholders by eliminating dilution from fractional share adjustments and simplifying equity structures.
Apr 17
8-K
Unknown — 8-K Filing
VNRX announced a potential reverse stock split (1-for-5 to 1-for-20 ratio) at board discretion, which typically signals financial distress or Nasdaq compliance issues and dilutes shareholder value.
Apr 1
8-K
Unknown — 8-K Filing
VolitionRx released FY2025 financial results and a business update, signaling management's confidence in operations; investors should monitor revenue trends and cash position to assess the epigenetics company's path to profitability.
Mar 31
8-K
VolitionRX Limited -- 8-K Filing
VolitionRX Limited issued immediately exercisable warrants expiring in 2030 through a private placement under Regulation D, diluting existing shareholders while raising capital without public market registration.
Feb 20
8-K · 8.01
!! High
VolitionRX Limited -- 8-K 8.01: Material Event / Announcement
VolitionRX Limited announced a material event on February 9, 2026, though specific details about the announcement's business impact on the company's operations or financial performance were not disclosed in the filing summary.
Feb 9
Valuation
Market Cap
$7.5M
Enterprise Value
$13.6M
P/E (TTM)
-0.33x
Forward P/E
—
PEG Ratio
0.04x
P/B
—
P/S
3.03x
P/FCF
-0.38x
EV/EBITDA
—
Shares Out
5.3M
Financials (TTM)
Revenue
$2.5M
Net Income
-$24.6M
EBITDA
-$20.6M
Free Cash Flow
-$19.8M
Op Cash Flow
-$19.7M
EPS Basic
$-4.40
EPS Diluted
$-4.24
EPS Forward
$-0.09
Gross Margin
89.7%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$6.9M
Total Liab.
$42.5M
Total Equity
-$35.6M
Cash
$1.1M
LT Debt
$7.3M
Book Value/Sh
$-6.66
Debt/Equity
-0.33x
Current Ratio
0.17
Quick Ratio
0.17
Returns & Growth
ROE
68.2%
ROA
-338.4%
ROIC
1236.7%
Rev Growth YoY
+40.0%
EPS Growth YoY
+29.0%
Price Returns
2W
+2.2%
1M
-32.7%
3M
-58.6%
6M
-74.4%
12M
-90.5%
Technicals
52W High
$15.50
52W Low
$1.21
50d MA
$2.09
200d MA
$5.34
RSI (14)
46.40
ATR (14)
$0.12
Beta
1.33
Avg Volume
340K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 7:58am
· Source: financialmodelingprep.com